Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...
Company and CMMI agreed to key terms to be offered to State Medicaid Agencies to support access to LYFGENIA™ gene therapy for sickle cell disease States can opt in to an outcomes-based agreement with ...
N2OFF, Inc. (NASDAQ: NITO) ('N2OFF” and the 'Company”), a drug discovery company that is also investing in solar energy ...
CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.
The business model will focus on selling 3D bio-printers and bio-inks designed to develop delicious, nutritious, safe, and consistent cultivated meat from ethically harvested cells. 3D bio-printers: ...
BLR Bio LLC has announced new data on BLR-200, its lead compound for systemic sclerosis and lung fibrosis. In the new study, BLR-200 demonstrated the ability to reduce key disease tissue markers for ...
True patient-centricity will drive commercial success as CGT moves beyond first-generation therapies. Current timelines in CGT, from diagnosis to treatment, can exceed six months, often compounded by ...
For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise ...
UBC Okanagan researchers have developed a 3D bio-printed model that closely mimics the complexity of natural lung tissue, an innovation that could transform how scientists study lung disease and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback